Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL)

  • Nicholas WrightEmail author
  • Ensi Voshtina
  • Gemlyn George
  • Arun Singavi
  • Joshua Field
Case Report


Chronic lymphocytic leukemia (CLL) can trigger autoimmune phenomena, with immune thrombocytopenia (ITP) the most common presentation. Upon cessation of CLL therapy, including ibrutinib, autoimmune flares can occur. In a 68-year-old man with CLL, ibrutinib was held for 2 weeks prior to elective shoulder surgery. Eleven days after stopping therapy, he presented with a purpuric rash on his right hip, buttock, and lower extremities. He experienced two episodes of seizure activity while hospitalized. MRI brain demonstrated patchy areas of altered signal involving deep white matter and sub-cortical white matter structures concerning for cerebral vasculitis. Although there was no evidence of hemolysis, serum cold agglutinin titer was elevated at > 1:512 and cryoglobulin levels were positive at 36%. He was diagnosed with type I cryoglobulinemia and treated with rituximab, plasmapheresis, methylprednisolone, and ibrutinib was restarted. This regimen resolved his symptoms. A rare complication of CLL is the production of cryoglobulins, which can present at initial diagnosis or in relapsed disease. Our case demonstrates that the cessation of ibrutinib therapy, even for a short time, can precipitate complications. To our knowledge, we report the first case of a patient with well-controlled CLL who rapidly developed cryoglobulinemic vasculitis after stopping ibrutinib therapy.


CLL Ibrutinib Cryoglobulinemia Cold agglutinin 


Compliance with ethical standards

Conflict of interests

The authors have no conflicts of interest to report.


  1. 1.
    Jemal A, Siegal R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.CrossRefGoogle Scholar
  2. 2.
    Zent CS, Kay NE. Autoimmune complications in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol. 2010;23(1):47–59.CrossRefGoogle Scholar
  3. 3.
    Ruzickova S, Pruss A, Odendahl M, Wolbart K, Burmester GR, Scholze J, et al. Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. Blood. 2002;100(9):3419–22.CrossRefGoogle Scholar
  4. 4.
    Berentsen S, Bø K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the “idiopathic” type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105(5):354–62.CrossRefGoogle Scholar
  5. 5.
    Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37.CrossRefGoogle Scholar
  6. 6.
    Lewis FB, Schwartz RS, Dameshek W. X-radiation and alkylating agents as possible “trigger” mechanisms in the autoimmune complications of malignant lymphophroliferative disease. Clin Exp Immunol. 1966;1(1):3–11.Google Scholar
  7. 7.
    Barcellini W, Capalbo S, Agostinelli RM, Mauro FR, Ambrosetti A, Calori R, et al. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica. 2006;91(12):1689–92.Google Scholar
  8. 8.
    Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2016;30(2):346–50.CrossRefGoogle Scholar
  9. 9.
    Sato R, Jacob J, Gaballa S. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;59(7):1–4.Google Scholar
  10. 10.
    Brouet J-C, Clauvel J-P, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57(5):775–88.CrossRefGoogle Scholar
  11. 11.
    Meltzer M, Franklin EC. Cryoglobulinemia—a study of twenty-nine patients. Am J Med. 1966;40(6):828–36.CrossRefGoogle Scholar
  12. 12.
    Morra E. Cryoglobulinemia. Hematol Am Soc Hematol Educ Progr 2005;1(1):368–72.CrossRefGoogle Scholar
  13. 13.
    Xu W, Wang Y-H, Fan L, Fang C, Zhu DX, Wang DM, et al. Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia. Leuk Res. 2011;35(8):1060–5.CrossRefGoogle Scholar
  14. 14.
    Michael AB, Lawes M, Kamalarajan M, Huissoon A, Pratt G. Cryoglobulinaemia as an acute presentation of waldenstrom’s macroglobulinaemia. Br J Haematol. 2004;124(5):565.CrossRefGoogle Scholar
  15. 15.
    Payet J, Livartowski J, Kavian N, Chandesris O, Dupin N, Wallet N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54(4):767–77.CrossRefGoogle Scholar
  16. 16.
    Néel A, Perrin F, Decaux O, Dejoie T, Tessoulin B, Halliez M, et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol. 2014;89(2):156–61.CrossRefGoogle Scholar
  17. 17.
    Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57(5):775–88.CrossRefGoogle Scholar
  18. 18.
    Terrier B, Karras A, Kahn J-E, Guenno GL, Marie I, Benarous L, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore). 2013;92(2):61–8.CrossRefGoogle Scholar
  19. 19.
    Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25(1):10–8.CrossRefGoogle Scholar
  20. 20.
    Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology. 2008;2008(1):450–6.CrossRefGoogle Scholar
  21. 21.
    Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.CrossRefGoogle Scholar
  22. 22.
    O’Brien S, Jones JA, Coutre SE, Mato AR, Hillman P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409–18.CrossRefGoogle Scholar
  23. 23.
    Montillo M, O’Brien S, Tedeschi A, Byrd JC, Dearden C, Gill D, et al. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study. Blood Cancer J. 2017;7(2):e524.CrossRefGoogle Scholar
  24. 24.
    Manda S, Dunbar N, Marx-Wood CR, Danilov AV. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170(5):734–6.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Hematology/Oncology DepartmentMedical College of Wisconsin Affiliated HospitalsMilwaukeeUSA
  2. 2.WauwatosaUSA

Personalised recommendations